Aneuploidy Rates of in Vitro Matured Oocytes

Aneuploidy Clinical Trial

— IVM  

Official title:

Aneuploidy Rates of in Vitro Matured Oocytes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03860064
• Other study ID #: 1810-BCN-071-ME
• Status: Completed
• Start date: March 27, 2019
• Est. completion date: September 30, 2019

Study information

• Verified date: July 2019
• Source: IVI Barcelona
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In general, nearly 85% of retrieved oocytes are mature and reproductively useful after the retrieval, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively).

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Description:

Under controlled ovarian stimulation, patients with normal functional ovarian reserves produce a good number of oocytes at retrieval. However, in addition to quantity, oocyte maturity is an important variable for the success of reproductive technologies. In general, nearly 85% of retrieved oocytes are mature and reproductively useful, whereas the remaining percentage are still at metaphase I or germinal vesicle stage (MI: 4% and GV: 11 %, respectively). Due to the limited expectations held for in vitro maturation in said stimulated cycles, the rescue of immature oocytes is not widely used in current clinical practice and these oocytes are usually discarded due to the possibility of abnormal embryonic development or an increased rate of abortion.

The objective of our study is to assess if immature oocytes co-cultured with autologous cumulus cells is a safer strategy than just leaving the oocytes in standard culture.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: September 30, 2019
• Est. primary completion date: July 30, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• 18-35-year-old women

• BMI: >18 and < 30 kg/m2

• Normal female karyotype

• Normal uterus and ovaries at transvaginal ultrasound

Exclusion Criteria:

• > 35 years

• PCO syndrome carriers

• Null follicle aspiration

• History of chemotherapy or radiotherapy

Related Conditions & MeSH terms

• Aneuploidy

Intervention

Other:
• Non intervention
Non

Locations

Country	Name	City	State
Spain	Ivi Barcelona	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
IVI Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aneuploidy rate	Aneuploidy rate of the PB	The moment that the PB is extruded (between 1 hour and 50 hours after the denudation)